Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The global diabetic nephropathy market is experiencing significant growth, with revenues reaching around US$ 2.1 billion in 2023 and projected to climb to US$ 3.6 billion by 2032. This growth, marked ...

"A reduction or absence of ankle reflexes is strongly and independently linked to a decline in estimated glomerular ...

Research found that younger age at type 2 diabetes diagnosis is associated with higher risks of cardiovascular and all-cause ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can also protect the kidneys, regardless of diabetes status, finds a study led ...

A new study shows GLP-1 receptor agonists offer significant protection for kidneys and heart in both diabetic and ...

A worldwide movement is underway to oblige laboratories to provide an estimated glomerular filtration rate (eGFR) whenever serum creatinine concentration is measured at the request of a physician.

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

If your kidneys are damaged, this GFR will be lower ... Damage to your kidneys, whether from diabetes, high blood pressure, or other causes, is permanent. But with treatment and lifestyle changes ...

However, a more recent review examining the effects of cinnamon on blood sugar in people with type 2 diabetes, suggests that the overall benefits are inconclusive. While cinnamon was found to ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...